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Abstract 
Introduction: Melatonin (MEL) exerts beneficial effects on the gut partly by myorelaxative properties upon the smooth muscle. Its secre-
tion decreases with age, particularly in postmenopausal women.
This study was aimed at evaluating the effect of MEL on the symptoms of irritable bowel syndrome (IBS) in this group of patients.
Material and methods: The investigations were carried out in 80 postmenopausal women, aged 48–65 years, divided into two equal 
groups, diagnosed according to Rome Criteria III: i.e. patients with IBS with constipation predominant (IBS-C), and patients with IBS 
with diarrhoea predominant (IBS-D). The control group (C) included healthy women aged 46-65 years. In all subjects, 6-sulfatoxymela-
tonin (6-HMS) concentration urine was measured using ELISA assay. Patients in both groups over the course of six months were given 
melatonin (at a dose of 3 mg fasting and 5 mg at bedtime) or a placebo (double blind trial). Disease activity was evaluated after two, four 
and six months, using a ten-point scale to assess the main somatic symptoms: visceral pain, abdominal bloating, etc.
Results: The amounts of 6-HMS urine excretion (µg/24h) were: C 11.4 ± 3.0, IBS-C 10.2 ± 3.2, IBS-D 14.0 ± 6.3 (p < 0.05).
Correlation between values of symptoms score and contrary excretion of 6-HMS: IBS-C r = –0.714, IBS-D r = 0.409.
After six months in the IBS-C group, the intensity of visceral pain and abdominal bloating had decreased in 70% of patients (p < 0.01) 
and constipation in 50% of patients (p < 0.05). Beneficial changes in the IBS-D group were noted in 45% of patients, but this was not 
better compared to the placebo.
Conclusions: Melatonin can be used as part of the treatment of IBS, particularly in patients with constipation-predominant IBS. 
(Endokrynol Pol 2013; 64 (2): 114–120)
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Streszczenie
Wstęp: Melatonina (MEL) korzystnie wpływa na przewód pokarmowy, między innymi poprzez relaksujące działanie na mięśnie gładkie. 
Jej wydzielanie zmienia się wraz z wiekiem, szczególnie u kobiet w okresie pomenopauzalnym. Celem pracy była ocena wpływu mela-
toniny na objawy zespołu jelita nadwrażliwego w tej grupie kobiet.
Materiał i metody: Do badania włączono 80 kobiet, w wieku 48–65 lat. Zgodnie z Kryteriami Rzymskimi III wyodrębniono grupę z 
zaparciową postacią jelita nadwrażliwego (IBS-C, n = 40) i z biegunkową postacią tej choroby (IBS-D, n = 40). Grupę porównawczą (C) 
stanowiło 30 kobiet zdrowych, w tym samym wieku.
U wszystkich określono dobowe wydzielanie siarczanu 6-hydroksymelatoniny (6-HMS) z moczem.
Pacjentki w obu grupach przyjmowały przez 6 miesięcy melatoninę (3 mg rano i 5 mg wieczorem) lub placebo. W 2,4 i 6 miesiącu oceniono 
nasilenie dolegliwości (bóle i wzdęcia brzucha oraz deregulację wypróżnień), używając wizualnej 10 stopniowej skali.
Wyniki: Wydalanie 6-HMS z moczem (µg/24 h) wynosiło odpowiednio w grupach: C — 11,4 ± 3,0, IBS-C — 10,2 ± 3,2, IBS-D — 14,0 ± 
± 6,3 (p < 0,05).
Stwierdzono korelację między nasileniem objawów a wydzielaniem 6-HMS: ujemną IBS-C (r = –0,714), a dodatnią w grupie IBS-D (r = 0,409).
Po 6 miesiącach używania melatoniny w grupie IBS-C bóle i wzdęcia brzucha zmniejszyły się u 70% pacjentek, a zaparcia u 50% pacjentek.
W grupie IBS-D poprawę uzyskano u 45% pacjentek, a wyniki nie różniły się znacząco od tych w grupie przyjmującej placebo.
Wnioski: Melatonina może być stosowana w skojarzonej terapii IBS, szczególnie w postaci z zaparciami.   
(Endokrynol Pol 2013; 64 (2): 114–120)
Słowa kluczowe: menopauza, zespół jelita nadwrażliwego, melatonina, siarczan 6-hydroksymelatoniny
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Introduction
Irritable bowel syndrome (IBS) is a functional disease 
of complex pathogenesis. Genetic and environmental 
predispositions, chronic stress and depression are 
listed among IBS aetiological factors [1]. Brain-gut axis 
dysfunction is affected by various factors [2, 3]. Both 
elements of this axis can be responsible for IBS symp-
toms. In CNS, as well as in the gastrointestinal (GI) 
tract, there are a lot of the same neurotransmitters and 
hormones and their receptors which play a major role 
in the regulation of gastrointestinal tract functions [4]. 
Among hormones, melatonin is the one which is 
of importance. It is secreted by the pineal gland in cir-
cadian rhythm, regulated mainly by the effect of light 
[5]. Enterochromaffin cells (EC), widely distributed 
along the whole GI tract, are a markedly rich source 
of this indoleamine [6]. Melatonin is secreted from the 
GI tract under the effect of different stimuli, including 
nutritional ones, and it fulfils various enteroprotective 
functions. 
Melatonin manifests strong antioxidant and anti-
inflammatory [7–9] activity. Moreover, it regulates 
intestinal motility. The results of numerous studies 
have pointed to its inhibitory effect on smooth mus-
cle motor activity [10]. This effect can be induced by 
direct stimulation of specific receptors [11], regula-
tion of the activity of exchange channels Ca2+/K+ in 
cells [11, 12] as well as indirectly by visceral nervous 
system [13, 14]. This hormone blocks nicotinic ace-
tylcholine receptors in submucosal plexus neuronal 
endings and activates afferent fibres of the vagus 
nerve through the increase of CCK release and acti-
vation of CCK1R/CCK2R [15].
Harlow and Weekly [16] as well as Bubenik [17] 
showed that melatonin’s myorelaxative effect is directly 
proportional to the basic spontaneous tone and ampli-
tude of intestinal contractions in rats. In another study, 
Drago et al. [18] observed that melatonin in low doses 
accelerated, and in high doses slowed, the intestinal 
transit in the experimental models in animals. It also 
exerts a modulating effect on visceral sense [19].
Visceral hypersensitivity is a major element in IBS 
pathogenesis. The lowered pain threshold is observed 
in most patients with this disease which makes pain 
appear even with normal intestinal motility. 
The above properties of melatonin, recognised 
predominantly in experimental studies, have been at-
tempted to be used in medical practice.
A lot of clinical evaluations have pointed to the 
beneficial effect of melatonin in IBS therapy. Song et 
al. [20] described advantageous results of melatonin 
therapy (3 mg in the evening) as quickly as after two 
weeks, particularly decreased rectal sensitivity and 
reduced abdominal pain. Saha et al. [21] observed that 
the application of melatonin in an evening dose of 
3 mg for eight weeks improved significantly the IBS 
patients’ quality of life compared to the group receiv-
ing a placebo.
Lu at al. [22] also confirmed the efficacy of an even-
ing dose of 3 mg of melatonin in women with IBS. 
In this group, the prevalence of abdominal pain and 
distension as well as abnormal urge to defecate mark-
edly decreased. 
Considering also the results obtained by Radwan 
et al. [23] i.e. a significant reduction of urinary 6-HMS 
excretion both in patients with diarrhoea-predominant 
and constipation-predominant IBS, it appears that 
Table I. Characteristics of subjects enrolled on the study
Tabela I. Charakterystyka kliniczna osób włączonych do badania
Feature/parameters Healthy subjects Patients with IBS-C Patients with IBS-D
Number 30 40 40
Age (years) 36.5 ± 5.2 56.1 ± 6.2 54.5 ± 6.6
BMI 22.3 ± 1.2 23.4 ± 0.8 21.0 ± 0.9
FSH [UI/mL] 9.2 ± 6.0 88.5 ± 19.8 101.3 ± 512.6
Oestradiol [pg/mL] 112.3 ± 41.5 10.6 ± 2.9 13.0 ± 3.0
AST [U/L] 19.8 ± 5.1 23.6 ± 4.7 20.9 ± 5.8
ALT [U/L] 19.8 ± 5.1 18.8 ± 3.9 21.0 ± 5.1
GGTP [U/L] 27.2 ± 7.0 29.4 ± 9.5 30.1 ± 8.3
Ammonia [µg/dL] 29.8 ± 9.2 33.6 ± 10.2 26.7 ± 11.2
GFR [mL/min] 109.0 ± 9.7 105.4 ± 8.8 98.8 ± 7.5
BMI — body mass index; FSH — follicle-stimulating hormone; AST — aspartate aminotransferase; ALT — alanine aminotransferase; GGTP — gamma-glutamyl 
transferase; GFR — glomerular filtration rate
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low secretion of melatonin may be one of the causes 
of this disease, and this hormone can be administered 
substitutionally. 
Such a conclusion should be drawn cautiously 
because in an earlier study Stępień et al. [24] found 
the highest melatonin secretion in both forms of IBS 
compared to healthy subjects. This divergence could 
result from differences in the selection of patients for 
the examinations, also as regards gender and age. 
Furthermore, the psychoemotional state of the 
patients and the melatonin dose recommended for 
therapeutic purposes are also of importance.
Taking into account these reservations, our studies 
were undertaken in a homogeneous group of postmen-
opausal women considering urinary 6-HMS excretion as 
the exponent of melatonin synthesis and metabolism. 
The aim of our study was the evaluation of the influ-
ence of melatonin on the symptoms of irritable bowel 
syndrome in postmenopausal women.
Material and methods 
Eighty women were enrolled in this study, aged 48–65 
years (mean 55.3 ± 6.4), with irritable bowel syndrome 
(IBS) and in the postmenopausal period. The time that 
had passed since the last menstruation varied from 
2–14 years. Oestrogen deficit was observed in all pa-
tients: mean serum concentration of oestradiol-17b was 
11.6 ± 3.0 pg/mL, and increased FSH concentration 
to 94 ± 11.0 IU/dm3. The control group (C) included 
30 premenopausal women, aged 31–45 years (mean 
36.5 ± 5.2) without complaints or GI tract diseases. 
Based on the Rome III criteria [25], 40 women 
with constipation-predominant IBS (IBS-C) were dis-
tinguished and 40 with diarrhoea-predominant IBS 
(IBS-D). 
In all the subjects enrolled in the study, endoscopy 
examinations of the upper and lower parts of the in-
testinal tract were performed, histopathology of the 
colon mucosa was obtained, abdominal ultrasound was 
performed, as well as the following laboratory tests: 
blood cell count, CRP, glucose, electrolytes, bilirubin, 
urea, creatinine, cholesterol, triglycerides, TSH and 
activity of the following enzymes: AST, ALT, GGTP, FA, 
amylase and lipase. 
In patients with IBS-D, additionally parasitologi-
cal and bacteriological stool examinations, biopsy and 
histological analysis of the small bowel mucosa were 
performed. Patients with organic, metabolic and psychi-
atric diseases, as well as those on long-term treatment 
with pharmacological agents, and cigarette smokers, 
were excluded from the study. 
Seven days prior to the evaluations, all medications 
were withdrawn and the same diet was recommended 
in all subjects, particularly with a similar daily amount 
of products rich in L-tryptophan. On the day of the 
study, the subjects remained in the room with only a 
red light from 9.00 p.m. till 7.00 a.m. and the same liquid 
diet was administered (Nutridrink, Nutrica, Nether-
lands) in the amount of 3 × 400 ml of the caloric value 
of 1,800 kcal, and 1,500 mL of isotonic still water. At the 
same time, the 24 h urine collection was performed. 
Urine was kept at +4°C. Immediately after the end of 
24-hour collection, the volume of urine was measured, 
centrifuged and the samples were frozen at –70°C. The 
concentration of 6-HMS in the urine was measured by 
the ELISA method applying IBL antibodies (RE-54031, 
Immunological Laboratories) and Expert 99 MicroWin 
2000 reader (Biogenet). The obtained results were con-
verted from µg/mL to µg/24 h. 
After diagnostic investigations, melatonin was ad-
ministered to 20 patients in both groups in a morning 
dose of 3 mg and an evening dose of 5 mg and 20 pa-
tients received a placebo in the same dose regimen, in 
a double blind procedure for six months. The patients 
kept an observation diary in which they noted the 
intensification of three main somatic ailments: visceral 
pain, abdominal bloating and constipation or diar-
rhoea. To evaluate the effect of melatonin or placebo 
on the clinical picture of the disease, a ten-point Visual 
Analogue Scale (VAS) was used distinguishing mild 
(1–4 points), moderate (5–7 points) and severe (8–10 
points) stages.
The study was approved by the Ethical Committee 
of the Medical University in Lodz (No.: RNN 238/05/ 
/KB) and the enrolled patients signed written consent. 
The data was analysed statistically applying the 
Kruskal-Wallis and Mann-Whitney and chi-square tests 
using Statistica-Microsoft Co. software. 
Results 
The urinary 6-HMS excretion in the control group of 
women without GI tract ailments was 11.4 ± 3.0 µg/24 h 
(Fig. 1).
A similar result was obtained in the group of women 
with IBS-C — 10.2 ± 3.2 µg/24 h (p > 0.05). In the moder-
ate stage of this disease in 19 women, 6-HMS excretion 
was 13.5 µg/24 h, whereas in the severe stage it was 
significantly lower in 21 women — 9.3 ± 1.7 µg/24 h.
In IBS-D, the urinary 6-HMS excretion was higher 
than in healthy women and it was 14.0 ± 6.3 µg/24 h 
(p < 0.01). This difference was particularly pronounced 
in the group of 18 women with severe IBS-D — respec-
tively 11.42 ± 3.03 and 18.97 ± 5.70 µg/24 h.
We noted a negative correlation between values of 
symptoms score and contrary excretion of 6-sulfatox-
ymelatonin in patients with IBS-C; value of correlation 
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coefficient (r) was (minus) –0.714 (Fig. 2). In patients 
with IBS-D on the urinary this correlation was positive: 
r = 0.409 (Fig. 3).
In constipation-predominant IBS, melatonin 
decreased IBS symptoms more distinctly compared 
to placebo c2 = 29.901 and c2 = 56.798, respectively. 
These differences were statistically significant when 
evaluated in the four and six months of melatonin ad-
ministration (Fig. 4). After six months, total regression 
of abdominal pain was observed in 12 patients (60%). 
At the same time, abdominal bloating decreased in 
14 (70%) patients. Less favourable results concerned 
constipation because only in one person was the full 
effect noted, while in nine there was an improvement 
in bowel movement.
Figure 1. 6-sulfatoxymelatonin (6-HMS) urinary excretion in 
healthy subjects (C) and in patients with irritable bowel syndrome 
with constipation (IBS-C) and diarrhoea (IBS-D) predominant; 
X¯ ± SD; *p < 0.05
Rycina 1. Wydalanie siarczanu 6-hydroksymelatoniny (6-HMS) 
z moczem u pacjentów z zespołem jelita nadwrażliwego w postaci 
zaparciowej (IBS-C) i biegunkowej (IBS-D); x¯  ± SD; *p < 0,01
Figure 2. Correlation between values of clinical index (symptoms 
score) and urinary excretion 6-sulfatoxymelatonin (6-HMS) in 
patients with irritable bowel syndrome with constipation (IBS-C) 
predominant
Rycina 2. Korelacja między wskaźnikiem nasilenia objawów 
a wydalaniem siarczanu 6-hydroksymelatoniny (6-HMS) z moczem 
u pacjentów z zaparciową postacią zespołu jelita nadwrażliwego (IBS-C)
Figure 3. Correlation between values of clinical index (symptoms score) 
and urinary excretion 6-sulfatoxymelatonin (6-HMS) in patients with 
irritable bowel syndrome with diarrhoea (IBS-D) predominant
Rycina 3. Korelacja między wskaźnikiem nasilenia objawów 
a wydalaniem siarczanu 6-hydroksymelatoniny (6-HMS) 
z moczem u pacjentów z biegunkową postacią zespołu jelita 
nadwrażliwego (IBS-D)
Figure 4. Comparison of treatment results after placebo and 
melatonin administration in irritable bowel syndrome patients 
with constipation (IBS-C) predominant; *p < 0.05; **p < 0.01
Rycina 4. Wyniki leczenia melatoniną postaci zaparciowej 
zespołu jelita nadwrażliwego w porównaniu z placebo; *p < 0.05; 
**p < 0.01
In diarrhoea-predominant IBS, a nine-week ad-
ministration of melatonin did not change significantly 
the clinical picture of the disease and the results were 
similar as in the group with placebo c2 = 24.412 and c2 
= 25.739 respectively (Fig. 5). 
Melatonin was well tolerated. Only two women 
from the IBS-C group felt slight symptoms of fatigue 
in the morning hours and one slight vertigo in the first 
week of the therapy.
Discussion 
The obtained results confirm the opinions of many 
researchers as to the beneficial effect of melatonin 
on the gastrointestinal tract, and the possibilities of 
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its use in the treatment of chronic diseases of this 
tract [26, 27].
Nevertheless, the effects of the treatment can vary 
and they can depend on the grade of its physiological 
secretion. The use of melatonin can be particularly justi-
fied in the case of its deficit in an organism [28]. Low 
secretion of melatonin at night has been found, among 
others, in oesophageal reflux disease [29], in functional 
dyspepsia and in duodenal ulcer disease [30, 31]. 
These changes should be related to individually dif-
ferentiated secretion of pineal melatonin. However, in 
the case of intestinal diseases, the amount of secreted 
melatonin depends on other factors, mainly local ones. 
The number of EC cells can be such a factor as they 
proliferate in intestinal diseases. The results of studies 
to date have pointed to a changeable number of EC 
cells also in patients with IBS [32]. Spiller et al. [33] 
found an increased number of these cells in subjects 
with diarrhoea-predominant IBS. In turn, El-Sahly 
et al. [34] observed a decreased number of EC cells in 
constipation-predominant IBS. 
In earlier studies, we demonstrated that secretion 
of melatonin in postmenopausal women is signifi-
cantly decreased, but its metabolism in the liver is not 
disturbed [35]. 
A negative correlation between 6-HMS excretion 
and intensification of ailments from the GI tract is an 
important observation. The lowest excretion of this me-
tabolite was found in women with persistent abdominal 
pain and sleep disorders. This may prove that melatonin 
deficit is one of the important factors of pathogenetic 
psychoemotional disorders in postmenopausal women. 
The time and the cause-effect dependence between 
the secretion of melatonin and sex hormones is a dif-
ferent issue. It is known that melatonin secretion is 
associated with the organism aging. It can indirectly 
affect gonadal activity via gonadoliberin and gon-
adotropins secretion [36]. The direct effect cannot be 
excluded either. Higher melatonin concentration in the 
ovarian vesicles fluid suggests that this hormone may 
also be synthesised in gonads [37]. These suggestions 
are supported by studies confirming the presence of 
precursor compounds (tryptophan, serotonin) as well as 
enzymes engaged in melatonin synthesis — serotonin 
N — acetyl-transferase and hydroxyindole-O-methyl 
transferase, in the human ovary homogenates [38]. The 
effect of melatonin on both synthesis and secretion of 
sex hormones by ovarian vesicles is not unequivocally 
established. Some authors have described its inhibitory 
action on progesterone secretion [39], while others have 
observed a stimulatory effect [40]. Most recent authors 
think that melatonin does not show any significant 
impact on oestradiol secretion. Moreover, Okatani et al. 
[41] observed a negative correlation between oestradiol 
and melatonin in premenopausal women. They also 
showed that oestradiol administration in postmeno-
pausal women reduced nocturnal increase of melatonin 
secretion. Luboshitzky et al. [42] observed that oestro-
gen treatment in women with hyperandregonaemia 
reduces usually elevated 6-HMS concentration in urine.
 It is supposed that the association between oes-
trogens and melatonin is not exclusively based on the 
feed-back mechanism, but is more complex, with the 
tropic hormones playing the role in this process. 
Irrespective of the above pathogenetic associations, 
the results of our studies have demonstrated marked 
melatonin deficit in some postmenopausal women. This 
justifies the usefulness of melatonin administration in 
a combined therapy of disorders associated with this 
period, particularly with the existing GI tract ailments 
after thorough analysis of the nature of these com-
plaints. Mean urinary excretion of 6-HMS in women 
with IBS-C did not differ significantly from healthy 
subjects, whereas it was higher in IBS-D patients; this is 
opposite to the observation of Radwan et al. [23]. These 
differences may be dependent on various agents such as 
the number of enterochromafin cells and its activity, di-
ets used during the period of examination, gender and 
age of patients, level of emotional disorders and others 
[43, 44]. The results of the treatment were more ben-
eficial in IBS-C patients. Thus, it can be supposed that 
the beneficial effect was associated with melatonin’s 
relaxative properties on the smooth muscles of the gut, 
which in consequence led to diminished abdominal 
distension. However, a positive melatonin effect on the 
psychoemotional sphere cannot be excluded because 
in this group of patients the placebo effect was also 
significant. Poor effect was obtained in the regulation 
of the rhythm of bowel movements both in the IBS-C 
Figure 5. Comparison of treatment results after placebo and 
melatonin administration in irritable bowel syndrome patients 
with diarrhoea (IBS-D) predominant; no statistical significance
Rycina 5. Wyniki leczenia melatoniną postaci biegunkowej zespołu 
jelita nadwrażliwego w porównaniu z placebo; brak znamienności 
statystycznej
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and the IBS-D group. Similarly, other researchers did 
not observe distinct changes in bowel movement in 
IBS subjects after 30 days of 3 mg/daily of melatonin 
administration [22]. To optimise the treatment it would 
be desirable to establish melatonin dose and the time of 
its administration. Most doctors recommend an evening 
dose of 3 mg so as not to disturb the circadian rhythm of 
endogenic melatonin release. Due to melatonin’s short 
half-life (30−60 min.) it is justified to administer it in 
divided doses twice a day [45]. Patients with IBS have 
disturbances of the gastrointestinal tract (abdominal 
pain, bloating, diarrhoea) during the day, but never at 
night. For this reason, a fasting dose of melatonin may 
have a beneficial influence on GIT function. Moreover, 
melatonin is mainly catabolised to 6-HMS which also 
manifests biological activity, particularly antioxidant, 
and its appropriate level can diminish some adverse 
processes in the GI tract. 
Therefore it appears that in selected cases recom-
mendation of morning doses of melatonin is justified. 
Administration of melatonin in a combined treatment 
of IBS is also justified, but mainly in constipation-pre-
dominant IBS. The role of inflammatory factors is more 
frequently indicated [46, 47]. The anti-inflammatory ef-
fect of melatonin is not sufficient in these cases, but the 
possibility of the use of this hormone in the combined 
treatment of IBS is not excluded.
Conclusions 
Melatonin can be used in the combined treatment of 
IBS, particularly in patients with constipation-predom-
inant IBS. 
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